- Home
- INDO vs SCYX Comparison
INDO vs SCYX Comparison
Compare INDO & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INDO
- SCYX
- Stock Information
- Founded
- INDO 2018
- SCYX 1999
- Country
- INDO Indonesia
- SCYX United States
- Employees
- INDO N/A
- SCYX N/A
- Industry
- INDO Oil & Gas Production
- SCYX Biotechnology: Pharmaceutical Preparations
- Sector
- INDO Energy
- SCYX Health Care
- Exchange
- INDO Nasdaq
- SCYX Nasdaq
- Market Cap
- INDO 41.5M
- SCYX 34.9M
- IPO Year
- INDO 2019
- SCYX 2014
- Fundamental
- Price
- INDO $2.92
- SCYX $1.12
- Analyst Decision
- INDO
- SCYX
- Analyst Count
- INDO 0
- SCYX 0
- Target Price
- INDO N/A
- SCYX N/A
- AVG Volume (30 Days)
- INDO 336.3K
- SCYX 199.8K
- Earning Date
- INDO 10-24-2025
- SCYX 11-05-2025
- Dividend Yield
- INDO N/A
- SCYX N/A
- EPS Growth
- INDO N/A
- SCYX N/A
- EPS
- INDO N/A
- SCYX N/A
- Revenue
- INDO $2,667,508.00
- SCYX $3,257,000.00
- Revenue This Year
- INDO N/A
- SCYX $422.61
- Revenue Next Year
- INDO N/A
- SCYX $240.56
- P/E Ratio
- INDO N/A
- SCYX N/A
- Revenue Growth
- INDO N/A
- SCYX N/A
- 52 Week Low
- INDO $2.10
- SCYX $0.66
- 52 Week High
- INDO $7.95
- SCYX $1.66
- Technical
- Relative Strength Index (RSI)
- INDO 50.78
- SCYX 74.20
- Support Level
- INDO $2.83
- SCYX $0.81
- Resistance Level
- INDO $3.10
- SCYX $0.88
- Average True Range (ATR)
- INDO 0.13
- SCYX 0.07
- MACD
- INDO 0.01
- SCYX 0.03
- Stochastic Oscillator
- INDO 32.35
- SCYX 62.33
About INDO Indonesia Energy Corporation Limited
Indonesia Energy Corp Ltd is an oil and gas exploration and production company focused on Indonesia. The company is an independent energy company engaged in the oil and gas business and holds two oil and gas assets through its subsidiaries in Indonesia: The Kruh Block and the Citarum Block. It has also identified a potential third exploration block known as the Rangkas area. . Its portfolio consists of Kruh Block and Citarum Block. The company generates its revenue from oil and gas sales.
About SCYX SCYNEXIS Inc.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.